Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review

• Main Authors: Lumin Wang (Author), Qining Qiu (Author), Dawei Yang (Author), Chang Cao (Author), Yanqin Lu (Author), Yulan Zeng (Author), Weiwen Jiang (Author), Yun Shen (Author), Yanrong Ye (Author)
• Format: Knjiga
• Izdano: Frontiers Media S.A., 2024-03-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.

Rapamycin, an established mTOR inhibitor in clinical practice, is widely recognized for its therapeutic efficacy. Ridaforolimus, a non-prodrug rapalog, offers improved aqueous solubility, stability, and affinity compared to rapamycin. In recent years, there has been a surge in clinical trials involv...